SSHO, ONXX, - CRWESelect.com Hot Stock Watch! - South Shore Resources Inc. and ...
14.06.10
Onyx Pharmaceuticals Inc. (NasdaqGS: ONXX)
ONXX reported today that the unalterable analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) go evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small apartment lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving comprehensive survival in the first-line setting.
ONXX announced that it will host a teleconference and webcast on Monday, June 14, 2010, at 9:00 a.m. Eastern Every now (6:00 a.m. Pacific Time) to provide an update on Nexavar® (sorafenib) tablets.
Their approved effect, Nexavar® (sorafenib) tablets, is a novel, oral multiple kinase inhibitor that targets proteins snarled in both tumor cell proliferation and angiogenesis. Nexavar is approved in more than 90 countries for the treatment of patients with unresectable liver cancer and in more than 95 countries for the treatment of patients with advanced kidney cancer.
Source: Penny Stock Live (blog)